ReviewTranslational lung cancer research2016
Is surgery still the optimal treatment for stage I non-small cell lung cancer?
Review in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Trial
- Racial disparities in staging, treatment, and mortality in non-small cell lung cancer.Translational lung cancer research · 2024Article
- Article
- A single institutional experience with central lung stereotactic body radiation therapy demonstrating encouraging results with increased inter-fraction time.Journal of thoracic disease · 2021Article
- Strategic Initiatives for Veterans with Lung Cancer.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2020Article
- Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study.OncoTargets and therapy · 2018Article
- Lobectomy: no port at all?Annals of translational medicine · 2017Article
- Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.Translational lung cancer research · 2017Review
- Stage I lung cancer-to operate or to radiate? that is the question.Journal of thoracic disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is debate about what is the optimal treatment for operable stage I non-small cell lung cancer (NSCLC). Although surgery has been the standard of care for centuries, recent retrospective and prospective randomized studies indicated that stereotactic ablative radiotherapy (SABR) could be an option for this group of patients with similar survival and less toxicities. However, to change the standard of care, more studies are needed and participating ongoing larger randomized studies is the best approach to resolve this controversy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.